Logo

American Heart Association

  15
  0


Final ID: MP2727

A Suppression-and-Replacement Platform Identifies Pathogenic Variants in the LMNA-Encoded Lamin A/C Ig-Like Domain as Drivers of Nuclear Distortion and Aggregation

Abstract Body (Do not enter title and authors here): Background: Pathogenic variants in LMNA-encoded lamin A/C cause a genetic cardiomyopathy marked by conduction disease, atrial and ventricular arrhythmias, and systolic dysfunction. The mechanisms underlying phenotypic differences between Ig-like and coiled-coil domain missense variants remains unclear. Here, we developed a novel suppression-and-replacement disease modeling (SupRep-DM) platform to screen LMNA missense variant function and prioritize mechanistically informative phenotypes.

Methods: LMNA-SupRep-DM is a dual-component lentiviral system that enables simultaneous knockdown of endogenous LMNA via an LMNA-targeted shRNA and replacement with an shRNA-immune mutant lamin A cDNA encoding the pathogenic variant of interest with HA-tag. HEK293T cells and iPSC-derived cardiomyocytes (iPSC-CMs) were transduced with 9 unique SupRep-DM constructs harboring variants in either the coiled-coil (E82K, K97E, R216C, H222P, T224I, R335W) or Ig-like (R471H, R541C, R541H) domains. Cells were stained using HA-specific antibodies, imaged by confocal microscopy, and analyzed for nuclear morphology, aggregate burden, and fluorescence intensity. Statistics: Dunnett’s test and one-way ANOVA.

Results: In HEK293T cells, 8/9 LMNA variants significantly reduced nuclear circularity (p< 0.05), most notably in K97E (-11%, n=89), R471H (-12%, n=62), and R541C (-9%, n=104). Additionally, K97E increased nuclear area (+24%) and R541C decreased it (−29%) vs wild-type (WT, p<0.0001). Lamin A intensity was significantly reduced in K97E, R471H, and R541C, but increased in T224I and R335W vs WT. In iPSC-CMs, Ig-fold variants R541C and R541H significantly reduced nuclear circularity (−28%, –34%), increased elongation (+42%, +49%), and elevated lamin A aggregates ~4–5-fold vs WT (p≤0.0005). R471H and the coiled-coil variant E82K also increased aggregate burden, while the remaining variants (K97E, R216C, H222P, T224I, R335W) showed no significant effects in iPSC-CMs.

Conclusions: LMNA missense variants cause domain-specific nuclear disruptions, with variants localizing to the Ig-like domain inducing nuclear deformities and consistent aggregation across both cellular models. Coiled-coil variants showed more variable, context-dependent effects. The more pronounced phenotypes in iPSC-CMs may reflect contraction-mediated stress absent in HEK293T cells. The SupRep-DM platform sensitively detects these structural changes, demonstrating its utility for mechanistic prioritization of LMNA variants.
  • Huynh, Trung  ( Mayo Clinic Alix School of Medicine , Rochester , Minnesota , United States )
  • Kim, Changsung  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Tester, David  ( MAYO CLINIC COLLEGE OF MEDICINE , Rochester , Minnesota , United States )
  • Castrichini, Matteo  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    Trung Huynh: DO NOT have relevant financial relationships | Changsung Kim: DO have relevant financial relationships ; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now) | David Tester: No Answer | Matteo Castrichini: DO NOT have relevant financial relationships | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Consultant:Nuevocor Therapeutics:Active (exists now) ; Consultant:Citizen Health:Active (exists now) | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:UpToDate:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Solid Biosciences:Active (exists now) ; Royalties/Patent Beneficiary:Prolaio:Active (exists now) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Past (completed) ; Consultant:Illumina:Active (exists now) ; Consultant:Bristol Myers Squibb:Past (completed) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Genomic Insights into Heritable Cardiomyopathies: From Disease Development to Novel Therapies

Monday, 11/10/2025 , 12:15PM - 01:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A Case of Clozapine-Induced Myocarditis: An Under-described Side Effect

Ibrahim Rand, Clearo Kellie

A Highly Selective and Orally Available HDAC6 Inhibitor, EKZ-102, Ameliorates Cardiac Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF

Elbatreek Mahmoud, Goodchild Traci, Lefer David, Evans Lauren, Richardson Thomas, James Rebecca, Schroeder Frederick, Wang Jianhong, Luterman Jim, Gilbert Tonya, Fisher Richard

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available